🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for HR+/HER2+ Early Breast Cancer

ABCSG 61 / TEODOR : Neoadjuvant TrEatment Optimization Driven by Circulating Tumor DNA and endOcrine Responsiveness NCT07084558NA14 sites📍 Vienna📍 Baden📍 Dornbirn Austrian Breast & Colorectal Cancer Study Group · Tests: blood sample for Signatera (TM) test, biopsy for Ki-67 assessment, FFPE tumor sample for Signatera (TM) test (archived) Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer NCT05306041Phase 262 sites📍 Essen📍 Augsburg📍 Berlin GBG Forschungs GmbH · Tests: Inavolisib, PHESGO, Endocrine therapy Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib NCT07237256Phase 3138 sites📍 Amiens📍 Angers📍 Argenteuil UNICANCER · Tests: Chemotherapy followed by endocrine therapy and ribociclib treatment, De-escalation CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS) NCT07019363Phase 31 site📍 Shanghai Fudan University · Tests: Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane), Standard endocrine therapy combined with CDK4/6 Inhib… Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer NCT07531693n/a1 site📍 Erlangen Institut fuer Frauengesundheit Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer NCT05878314n/a1 site📍 Tübingen University Hospital Tuebingen RADIANT: Pre-op Radiation With Abemaciclib and Letrozole NCT06139107Phase 14 sites📍 Belleville📍 Livingston📍 New Brunswick Mridula George, MD · Tests: Abemaciclib, Letrozole Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer NCT06341894Phase 21 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Dalpiciclib, Endocrine therapy Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests NCT07106632Phase 3105 sites📍 Brussels📍 Brussels📍 Charleroi UNICANCER · Tests: test-directed treatment: allocated treatment will depend on the PAM50 score result (centrally assessed) : chemo-endocri… Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer NCT04553770Phase 29 sites📍 Fullerton📍 Los Alamitos📍 Los Angeles Jonsson Comprehensive Cancer Center · Tests: Anastrozole, Therapeutic Conventional Surgery, Trastuzumab Deruxtecan Neoadjuvant SNF Precision Therapy Phase III NCT06913777Phase 31 site📍 Shanghai Fudan University · Tests: Targeted therapy agents: SNF2 -adebrelimab + famitinib; SNF3 -fluzoparib; SNF4 -apatinib, Chemotherapy (wP-EC) PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS NCT05792150n/a71 sites📍 Baden-Baden📍 Pforzheim📍 Stuttgart Women's Cancer Study Group GmbH Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer NCT07616427Phase 23 sites📍 Nanjing📍 Hangzhou📍 Ningbo Second Affiliated Hospital, Zhejiang University, School of … · Tests: Fovinaciclib, Aromatase Inhibitors, Trastuzumab + Pertuzumab RWE Non-Interventional Prospective Study of Ribociclib Effectiveness and Safety in Patients With HR+/HER2- Early Breast Cancer in Saudi Arabia NCT06797531n/a2 sites📍 Riyadh📍 Riyadh Novartis Pharmaceuticals · Tests: ribociclib Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study NCT07581834Phase 22 sites📍 Fuzhou📍 Chengdu Fujian Cancer Hospital · Tests: Dalpiciclib 125mg, Dalpiciclib 100mg, Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen The Benefits of Continued Use of Ovarian Function Suppression After 5 Years NCT06050109n/a1 site📍 Wuhan Hongmei Zheng, PhD · Tests: OFS continues to use group after 5 years use, Immunohistochemical detection of HR status Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies NCT07211178n/a16 sites📍 Birmingham📍 Whittier📍 Weston Tempus AI · Tests: There are no interventions in this observational study. The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World. NCT05263570n/a1 site📍 Shenyang Shengjing Hospital · Tests: Standard Therapy Evaluating the Effectiveness of Typology-based Coaching on Patients' Therapy Management NCT07708571NA3 sites📍 Augsburg📍 Erlangen📍 Hösbach Institut fuer Frauengesundheit · Tests: Typology-based coaching Skipping Hormone Therapy in Low-Risk Early Breast Cancer NCT07661927Phase 241 sites📍 Angers📍 Avignon📍 Bayeux UNICANCER · Tests: Removing Endocrine Therapy BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer NCT05977036NA1 site📍 St Louis Washington University School of Medicine · Tests: DiviTum® TKa assay A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence NCT06830720n/a287 sites📍 Wiener Neustadt📍 Innsbruck📍 Linz Novartis Pharmaceuticals · Tests: ribociclib + AI ± LHRH, abemaciclib + ET ± LHRH, ET mono ± LHRH Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) NCT05891093Phase 315 sites📍 Beijing📍 Chongqing📍 Fuzhou Fudan University · Tests: Fluzoparib, Anastrozole, Letrozole, Exemestane, Tamoxifen ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer NCT06970912Phase 21 site📍 Beijing Peking University People's Hospital · Tests: Dalpiciclib + Aromatase Inhibitor with ctDNA-Guided Therapy, Taxane-Based Neoadjuvant Chemotherapy A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) NCT06966700Phase 3331 sites📍 Gilbert📍 Phoenix📍 Tucson Merck Sharp & Dohme LLC · Tests: Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Carboplatin, Paclitaxel Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC NCT07242352Phase 333 sites📍 Mannheim📍 Tübingen📍 Esslingen am Neckar Women's Cancer Study Group GmbH · Tests: Elacestrant, Standard-of-care endocrine treatment Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer NCT06106477NA1 site📍 Milwaukee Medical College of Wisconsin · Tests: Intermittent Fasting Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer NCT06860529Phase 21 site📍 Zhengzhou Henan Cancer Hospital · Tests: Serplulimab, Epirubicin, Albumin Paclitaxel Impact of Exercise on Quality of Life of EBC Patients on Treatment With Adjuvant AI With or Without CDK4/6 Inhibitors NCT07215364NA5 sites📍 L'Hospitalet de Llobregat📍 Pamplona📍 Granada Spanish Breast Cancer Research Group · Tests: Training program Ablation Compare With Surgery for Early Breast Cancer NCT07484087NA1 site📍 Beijing Peking University People's Hospital · Tests: breast conserving surgery, cryo-thermal ablation
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy